A familial Mediterranean fever genetic test examines the MEFV gene for variants linked to recurrent inflammatory attacks. Familial Mediterranean fever, or FMF, is an autoinflammatory disorder that often causes short episodes of fever with severe abdominal, chest, or joint pain. Genetic testing can support the diagnosis, especially when symptoms are typical but clinical criteria are not conclusive. It can also help evaluate relatives, clarify reproductive risk, and guide follow-up for people with higher-risk genotypes. The result is not always simple: two disease-associated variants can strongly support FMF, one variant may still be clinically meaningful, and a negative result does not rule the condition out. MEFV contains many common variants whose effects range from clearly pathogenic to uncertain or low penetrance. For that reason, the report must be interpreted alongside the person’s attack pattern, ancestry, inflammatory markers, treatment response, and family history rather than used as a stand-alone yes-or-no answer.
- The test looks for MEFV variants that alter pyrin, a protein that helps control innate immune inflammation.
- Two pathogenic or likely pathogenic variants strongly support FMF, but some affected people have only one detectable variant.
- A negative MEFV result does not exclude FMF when the clinical pattern is convincing.
- Common exon 10 variants such as p.Met694Val may be associated with earlier or more severe disease.
- No fasting is usually needed; testing commonly uses blood, saliva, or a cheek swab.
- Persistent fever, chest pain, severe abdominal pain, or signs of kidney disease require medical assessment regardless of the genetic result.
Table of Contents
- What the MEFV Genetic Test Measures
- When MEFV Testing Is Used
- Test Methods and Sample Collection
- How to Interpret MEFV Results
- What Genotype Can and Cannot Predict
- How Results Affect Diagnosis and Treatment
- Family Testing and Pregnancy Risk
- Limitations, Common Errors, and Next Steps
What the MEFV Genetic Test Measures
The test analyzes MEFV, the gene that provides instructions for making pyrin. Pyrin is found mainly in cells of the innate immune system, the body’s rapid first-line defense against infection and tissue injury. It helps regulate an inflammatory protein complex called the pyrin inflammasome. Disease-associated MEFV variants can make this pathway too easy to activate, causing repeated bursts of inflammation without an infection or autoimmune antibody trigger.
FMF attacks usually begin in childhood or adolescence, although onset can occur later. Episodes often last about 12 to 72 hours and may include:
- Fever
- Severe abdominal pain from inflammation of the abdominal lining
- Sharp chest pain that worsens with breathing
- Painful swelling of one or more large joints, especially ankles or knees
- A red, tender rash on the lower legs or feet
- Muscle pain
- Scrotal pain or swelling
People are commonly well between attacks, although low-grade inflammation can continue silently. Untreated or poorly controlled inflammation can lead to AA amyloidosis, in which serum amyloid A protein deposits in organs, especially the kidneys. Protein in the urine may be the first sign.
MEFV testing looks for changes in the gene’s DNA sequence. Frequently discussed variants include p.Met694Val (M694V), p.Met680Ile (M680I), p.Val726Ala (V726A), p.Met694Ile (M694I), and p.Glu148Gln (E148Q). Their clinical significance is not identical. Some have strong evidence for causing classic FMF, while others show lower penetrance, variable effects, or disagreement among laboratories.
Historically, FMF was described as an autosomal recessive condition, meaning two altered MEFV copies were usually expected. Current evidence is more complex. Many people with classic symptoms have only one identified pathogenic variant, and some variants can contribute to disease in a dominant or dose-dependent way. The test therefore provides evidence for or against the diagnosis but does not replace clinical assessment.
A clinician may order MEFV alone or include it in a periodic fever syndrome genetic panel. A panel can be useful when the pattern overlaps with other autoinflammatory disorders, especially when attacks are unusually long, begin in infancy, include prominent rash or eye inflammation, or do not respond as expected to colchicine.
When MEFV Testing Is Used
MEFV testing is most useful when a person’s history suggests FMF. The test is not intended as a general explanation for every unexplained fever. Clinicians first consider the duration, frequency, associated pain, age at onset, ancestry, inflammatory markers, family history, and whether infections or other diseases better explain the episodes.
Testing may be appropriate when a person has:
- Repeated self-limited fevers lasting one to three days
- Recurrent abdominal, pleuritic chest, or large-joint attacks
- Elevated C-reactive protein, erythrocyte sedimentation rate, or serum amyloid A during attacks
- A first-degree relative with confirmed FMF
- An ancestry in which FMF is more common, including Turkish, Armenian, Arab, Jewish, North African, Greek, Italian, or other Mediterranean backgrounds
- Unexplained AA amyloidosis or persistent protein in the urine
- A partial or strong response to colchicine but an uncertain diagnosis
- Symptoms suggestive of an inherited autoinflammatory syndrome
Ancestry can raise suspicion, but it should not be used as a gatekeeper. FMF occurs worldwide, and migration and mixed ancestry make rigid ethnic categories unreliable. A person with a classic clinical pattern deserves evaluation even without known Mediterranean ancestry.
Genetic testing can serve several different purposes:
Diagnostic testing supports or clarifies the diagnosis in a symptomatic person. A molecular result is strongest when it matches the clinical picture.
Predictive or family testing checks relatives for a known familial variant. The result may help explain symptoms or identify relatives who need clinical review, but finding a variant in an asymptomatic person does not always predict future disease.
Reproductive testing determines whether biological parents carry variants that could be passed to children. This is especially relevant when one partner has two pathogenic MEFV variants or when both partners come from families with FMF.
Complication assessment may use genotype as one part of estimating amyloidosis risk. It never replaces urine protein testing, kidney function tests, or monitoring of inflammation.
MEFV testing should not delay urgent care. Severe abdominal pain can mimic appendicitis, chest pain can have cardiac or pulmonary causes, and fever may reflect infection. A known FMF diagnosis does not make every episode an FMF attack.
Test Methods and Sample Collection
Most MEFV tests use DNA from blood, saliva, or cheek cells. No fasting is normally required, and medications usually do not change the DNA result. The laboratory may ask for a clean saliva sample with no food, drink, gum, tobacco, or toothbrushing for about 30 minutes beforehand.
The testing strategy can greatly affect what is found.
Targeted variant panel
A targeted panel checks a limited group of common MEFV variants, often concentrated in exons 2, 3, 5, and 10. It may be faster and less expensive, and it can detect many variants seen in high-prevalence populations. Its weakness is that it misses rare variants outside the selected list. A “negative FMF panel” may therefore mean only that several common variants were absent.
Full MEFV sequencing
Full-gene sequencing reads the protein-coding regions and nearby splice boundaries. It is more likely to detect rare single-nucleotide changes and small insertions or deletions. Many laboratories begin with sequencing when the clinical suspicion is substantial or ancestry is mixed.
Deletion and duplication analysis
Large deletions or duplications in MEFV are uncommon, but some laboratories add copy-number analysis when sequencing is negative or when their assay includes it routinely. The report should state whether this type of change was assessed.
Multigene panel, exome, or genome sequencing
A multigene autoinflammatory panel examines MEFV with genes associated with conditions such as TNF receptor-associated periodic syndrome, mevalonate kinase deficiency, cryopyrin-associated periodic syndromes, and others. Exome or genome sequencing may be considered when symptoms are atypical, several systems are involved, or previous testing was unrevealing.
The usual process includes pretest review, sample collection, DNA analysis, variant classification, and post-test interpretation. Turnaround time is often two to six weeks, depending on the laboratory and test breadth.
Before testing, ask whether the laboratory:
- Sequences all clinically relevant MEFV exons
- Reports coverage gaps
- Detects small insertions and deletions
- Performs deletion and duplication analysis
- Uses current MEFV nomenclature and a stated reference transcript
- Reports variants of uncertain significance
- Distinguishes pathogenic variants from low-penetrance or risk alleles
- Offers family testing to determine whether two variants are on the same or opposite gene copies
Two variants may need phase analysis. Variants in trans are on opposite chromosome copies, one inherited from each parent. Variants in cis are on the same chromosome copy. This distinction can affect inheritance counseling and sometimes diagnostic interpretation. Testing parents or other relatives may establish phase.
How to Interpret MEFV Results
MEFV reports usually classify each variant as pathogenic, likely pathogenic, uncertain significance, likely benign, or benign. Some laboratories also describe certain variants as risk alleles or low-penetrance variants because a simple five-tier label does not fully capture their behavior.
| Result pattern | Usual meaning | Typical response |
|---|---|---|
| Two pathogenic or likely pathogenic variants | Strong molecular support for FMF, especially when variants are in trans and symptoms fit. | Confirm phase when needed, assess disease activity, and begin or continue specialist-guided care. |
| One pathogenic or likely pathogenic variant | May support FMF but is not conclusive by itself; some affected people have only one detectable variant. | Interpret with clinical criteria, consider comprehensive testing, and review response to treatment. |
| One or more uncertain variants | Evidence is insufficient to determine whether the change causes disease. | Do not diagnose or exclude FMF from the VUS alone; consider family studies and periodic reanalysis. |
| No reportable variant | FMF becomes less likely but is not ruled out. | Reassess test coverage, clinical criteria, alternative diagnoses, and possible colchicine trial. |
| Variant found in an asymptomatic relative | May indicate carrier status or susceptibility, but future symptoms cannot be predicted reliably. | Provide counseling and symptom-based follow-up rather than assuming disease. |
Two disease-associated variants
Two pathogenic or likely pathogenic variants, especially in trans, provide strong evidence for FMF. The result is most convincing when attacks are typical. Molecular confirmation can prevent repeated emergency evaluations, support long-term colchicine use, and prompt monitoring for subclinical inflammation and kidney complications.
The same genotype does not guarantee the same illness in two relatives. Age at onset, attack frequency, amyloidosis risk, treatment response, environment, ancestry, other genes, and adherence all influence the phenotype.
One pathogenic variant
A single pathogenic variant creates one of the most common interpretation challenges. Up to a substantial minority of clinically diagnosed patients have only one detectable MEFV variant. Possible explanations include a second variant missed by the assay, a noncoding or structural change, a dominant effect of the detected variant, additional genetic modifiers, or a clinical diagnosis that overlaps with another condition.
A single variant should neither automatically confirm nor dismiss FMF. The clinician should review whether attacks meet validated clinical criteria, whether inflammatory markers rise during episodes, whether the person is symptom-free between attacks, and whether colchicine produces a meaningful response.
Variants of uncertain significance and debated alleles
A VUS is not proof of disease. Computational predictions, rarity, and location in the gene may raise suspicion, but stronger evidence is needed. Family segregation, functional studies, repeated observations in affected people, and population frequency can change classification over time.
MEFV includes variants that are common in some populations and show incomplete penetrance. E148Q is a well-known example with variable interpretation. It may contribute to symptoms in some contexts, particularly with another variant, but it is also present in healthy people. The report should not be reduced to “mutation present” without its classification and supporting evidence.
A pathogenic, benign, or uncertain variant result describes the evidence about a DNA change. It does not by itself measure how severe a person’s attacks will be.
Negative result
A negative result means no reportable variant was detected by that assay. It may reflect a true absence of recognized MEFV disease variants, but it can also result from limited panel content, poor coverage, deep intronic variants, structural changes, mosaicism, or current scientific limits.
Clinical FMF can still be diagnosed when the pattern is compelling. Conversely, a negative test should encourage a careful search for infection, inflammatory bowel disease, autoimmune disease, malignancy, cyclic neutropenia, porphyria, hereditary angioedema, and other periodic fever syndromes when the presentation is atypical.
What Genotype Can and Cannot Predict
Certain MEFV genotypes correlate with disease features at a population level, but they do not provide a precise personal forecast. The clearest association involves p.Met694Val, particularly when present on both gene copies. This genotype has often been linked with earlier onset, more frequent attacks, arthritis, and a higher risk of AA amyloidosis if inflammation is not controlled.
That information can justify closer monitoring, but it should not create fatalism. Regular colchicine treatment greatly reduces attacks and the risk of amyloidosis. A person with a higher-risk genotype who takes effective therapy and receives monitoring may do well, while someone with a milder genotype can still have significant disease.
Genetic testing cannot reliably predict:
- The exact age symptoms will start
- How often attacks will occur
- Which organs will be involved
- Whether every relative with the same variants will become symptomatic
- The exact colchicine dose required
- Whether a person will be completely colchicine responsive
- Whether amyloidosis will develop
Risk assessment should combine genotype with persistent inflammation, serum amyloid A levels when available, C-reactive protein, attack frequency, family history of amyloidosis, kidney findings, and adherence to treatment. Environmental and regional factors may also affect complication rates.
Some people carry two MEFV variants but remain asymptomatic or have only mild symptoms. This is called reduced penetrance. It is especially important during family screening, because identifying a genotype does not automatically establish active disease. Asymptomatic relatives may need education and individualized follow-up rather than immediate lifelong treatment.
The reverse is also true: a person can have typical FMF without two clearly pathogenic variants. The absence of a textbook genotype should not outweigh repeated short attacks of serositis, objective inflammation, and a strong treatment response.
How Results Affect Diagnosis and Treatment
FMF remains a clinical diagnosis supported by genetics. Physicians use validated criteria such as Tel Hashomer, Livneh, pediatric criteria, or Eurofever/PRINTO classification frameworks. Genetic results can strengthen the diagnosis, but they should be considered with attack characteristics and laboratory evidence.
Colchicine is the standard long-term treatment. It is usually started once a clinical diagnosis is made rather than withheld until perfect molecular confirmation. Daily treatment reduces attack frequency and, most importantly, helps prevent AA amyloidosis. It must be taken consistently, including between attacks.
The genetic result may influence care by:
- Increasing confidence in the diagnosis
- Supporting earlier treatment in a person with typical attacks
- Prompting closer monitoring with higher-risk genotypes
- Identifying relatives who should be evaluated
- Helping distinguish FMF from another inherited fever syndrome
- Providing specific variants for prenatal or preimplantation testing
It usually does not determine the colchicine dose by itself. Dose selection depends on age, body size, attack control, persistent inflammation, kidney and liver function, tolerability, drug interactions, and adherence. Colchicine toxicity can be serious, especially with certain antibiotics, antifungals, transplant drugs, or impaired kidney function. People should not change the dose based on a genetic report without medical guidance.
Monitoring commonly includes attack frequency, side effects, complete blood count, liver enzymes, kidney function, urine protein, C-reactive protein, and serum amyloid A when available. Persistent inflammation between attacks matters even when symptoms seem controlled.
A person is not considered colchicine resistant simply because occasional attacks continue. Clinicians first confirm adherence, appropriate dose, correct diagnosis, and ongoing inflammation. For true colchicine-resistant or intolerant disease, interleukin-1 blocking medicines may be considered under specialist care.
A positive MEFV test does not explain every future symptom. New severe chest pain, prolonged fever, focal abdominal tenderness, breathing difficulty, neurologic changes, or dehydration still require evaluation for other causes.
Family Testing and Pregnancy Risk
MEFV results can be relevant to parents, siblings, children, and reproductive partners. The first step is to share the complete laboratory report, including the exact variant names and classifications. Testing relatives for the documented family variants is more informative than ordering an unrelated limited panel.
When a person has two pathogenic variants in trans, each biological child will inherit at least one of those variants. Whether a child is at risk of FMF depends on the other parent’s MEFV status and on the penetrance of the specific variants.
In a traditional autosomal recessive scenario where both parents each carry one pathogenic variant, every pregnancy has:
- A 25% chance of inheriting both variants and being at risk for FMF
- A 50% chance of inheriting one variant
- A 25% chance of inheriting neither familial variant
MEFV inheritance can be less predictable than this simple model because some variants show reduced penetrance or dominant effects. Reproductive counseling should use the exact variants, not only the statement that “FMF runs in the family.”
Testing may be considered before pregnancy, during pregnancy, or as part of fertility treatment. Options for a couple with a meaningful chance of an affected child can include natural conception, prenatal diagnosis, IVF with preimplantation genetic testing for monogenic disease, donor gametes, adoption, or proceeding without embryo or prenatal testing.
Prenatal diagnosis usually requires that the familial variants are known and classified well enough for testing. Chorionic villus sampling or amniocentesis can determine the fetal genotype. The result may not predict exact severity, especially for lower-penetrance variants.
Family testing can also uncover asymptomatic people with one or two variants. Such results require careful counseling. Healthy carriers generally do not need FMF treatment solely because of a single variant. Relatives with two variants may need a clinical review and inflammation assessment, but treatment decisions depend on symptoms, genotype, and expert judgment.
FMF carrier or family testing is related to an autosomal recessive genetic test, although MEFV’s variable penetrance means the classic 25% model does not describe every variant combination perfectly.
Limitations, Common Errors, and Next Steps
The main limitation of MEFV testing is that the gene has many variants with uneven evidence. A technically accurate result can still be clinically difficult to interpret. The most common errors come from treating the report as more definitive than it is.
Do not equate any MEFV change with FMF. Benign variants and low-penetrance alleles are common. The classification, genotype, phase, and clinical pattern matter.
Do not rule out FMF after a small targeted panel. A test that examined five or twelve variants is not equivalent to full sequencing. Review the assay before accepting a negative result.
Do not diagnose an asymptomatic relative from genotype alone. Reduced penetrance means some people with disease-associated variants never develop classic attacks.
Do not ignore a one-variant result. One pathogenic variant may support the diagnosis in a person with classic symptoms, but it should trigger careful clinical interpretation and consideration of broader testing rather than an automatic conclusion.
Do not use genotype as a substitute for kidney monitoring. Even a reassuring genotype cannot exclude ongoing inflammation or amyloidosis. Urine protein and inflammatory markers remain essential.
Do not stop colchicine because attacks improve. The preventive effect depends on regular use. Treatment changes should be supervised because silent inflammation can persist.
After a positive or uncertain result, useful next steps include:
- Confirm the exact variant names, classifications, and whether one or two variants were found.
- Determine whether two variants are in cis or trans when phase affects interpretation.
- Compare the genotype with validated clinical criteria and attack records.
- Check inflammation during attacks and between attacks.
- Assess urine protein and kidney function.
- Review colchicine use, dose, adherence, side effects, and drug interactions.
- Consider an autoinflammatory gene panel if the phenotype is atypical or testing is incomplete.
- Offer targeted testing and counseling to appropriate relatives.
- Ask whether the laboratory provides reclassification updates.
A symptom diary can make the genetic result more useful. Record fever temperature, duration, pain location, joint swelling, rash, possible triggers, medications, and laboratory results. FMF attacks are often recognizable by their short, stereotyped pattern. Documentation helps distinguish true inflammatory attacks from infections, medication effects, chronic pain, and unrelated conditions.
Seek prompt medical care for a first severe attack, fever lasting longer than expected, persistent vomiting, dehydration, breathing difficulty, crushing chest pain, a rigid abdomen, reduced urine output, swelling, blood in the urine, or pregnancy-related concerns. Genetic testing clarifies inherited risk; it does not replace urgent evaluation of dangerous symptoms.
References
- EULAR/PReS endorsed recommendations for the management of familial Mediterranean fever (FMF): 2024 update 2025 (Guideline)
- Familial Mediterranean Fever: How to Interpret Genetic Results? How to Treat? 2022 (Review)
- Familial Mediterranean Fever in Childhood 2024 (Review)
- Familial Mediterranean Fever 2023 (Review)
- Familial Mediterranean Fever (FMF): Emerging Concepts and the New Era of Targeted Therapies 2025 (Review)
- Familial Mediterranean Fever 2016 (Review)
Disclaimer
This article is educational and does not diagnose familial Mediterranean fever or recommend a specific treatment. MEFV results require interpretation with symptoms, inflammatory markers, kidney monitoring, ancestry, family history, and the exact laboratory method. Do not start, stop, or change colchicine or other anti-inflammatory treatment without guidance from a qualified clinician.
